Amgen, Lilly crook in upbeat data connected rival psoriasis drugs FierceBiotech In the hunt to develop targeted drugs against plaque psoriasis , Amgen ($AMGN) and Eli Lilly ($LLY) both said their experimental biologics met the main goals of their respective mid-stage studies. And the positive data from the studies, both according in ... Amgen Announces Phase 2 Study Results for Brodalumab in average to Severe ... Pr Newswire (press release) each 4 news articles » Link To Article
No comments:
Post a Comment